Vanda Pharmaceuticals (VNDA) Other Non-Current Liabilities (2012 - 2026)

Vanda Pharmaceuticals has disclosed Other Non-Current Liabilities across 14 years of filings, most recently posting $10.1 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $10.1 million, up 9.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.1 million (up 9.54% YoY), and the FY2025 annual result was $9.5 million, down 0.56% from the prior year.
• Other Non-Current Liabilities came in at $10.1 million for Q1 2026 at Vanda Pharmaceuticals, up from $9.5 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $11.0 million in Q3 2025 to a low of $1.0 million in Q1 2022.
• The 5-year median for Other Non-Current Liabilities is $8.8 million (2024), against an average of $7.7 million.
• Across the five-year window, Other Non-Current Liabilities tumbled 61.09% in 2022 and surged 540.08% in 2023, its largest moves.
• Vanda Pharmaceuticals' Other Non-Current Liabilities stood at $6.8 million in 2022, then rose by 29.81% to $8.8 million in 2023, then increased by 8.61% to $9.6 million in 2024, then declined by 0.56% to $9.5 million in 2025, then advanced by 6.23% to $10.1 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $10.1 million (Q1 2026), $9.5 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.